Table 1.

Baseline and end-Phase A (20 weeks) clinical assessment ratings in responders (n=22) and non-responders (n=22) to open label haloperidol treatment.

Rating Scales	Responders		Non-responders
	Baseline Mean (SD)	End- Phase A Mean (SD)	Baseline Mean (SD)	End- Phase A Mean
Sum of three target symptoms	14.5 (1.2)	5.9 (0.9)	14.6 (1.3)	10.8 (3.3)
BPRS total	26.6 (5.5)	19.0 (2.7)	28.8 (6.3)	27.2 (6.9)
BPRS psychosis factor	5.9 (2.5)	3.6 (0.9)	7.0 (3.0)	6.2 (3.7)
BPRS hostile suspiciousness factor	11.1 (3.0)	6.0 (1.2)	11.3 (2.6)	8.4 (2.9)
UPDRS total	0.8 (0.8)	0.7 (1.0)	0.5 (0.6)	0.7 (0.8)
Mini Mental State Exam (0–30)	12.9 (6.3)	12.3 (6.3)	12.5 (6.0)	13.8 (5.3)

Target symptoms were each score on a 0–6 scale (absent to extreme), sum score range 0–18.

BPRS: Brief Psychiatric Rating Scale.

BPRS psychosis factor excluded the item for conceptual disorganization because this symptom often occurs in AD in the absence of psychosis.

UPDRS: Unified Parkinson’s Disease Rating Scale.